What is Resmed's earnings per share (EPS)?

Resmed (RSMDF) reported diluted earnings per share of $9.51 for fiscal year 2025. This represents a 37.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Resmed Financials

RSMDF

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE June

This page shows Resmed (RSMDF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 79/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Resmed has an operating margin of 32.8%, meaning the company retains $33 of operating profit per $100 of revenue. This strong profitability earns a score of 95/100, reflecting efficient cost management and pricing power. This is up from 28.2% the prior year.

Growth

Resmed's revenue grew 9.8% year-over-year to $5.1B, a solid pace of expansion. This earns a growth score of 50/100.

Leverage

100

Resmed carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.44, Resmed holds $3.44 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 67/100.

Cash Flow

100

Resmed converts 32.3% of revenue into free cash flow ($1.7B). This strong cash generation earns a score of 100/100.

Returns

Resmed's ROE of 23.5% shows moderate profitability relative to equity, earning a score of 63/100. This is up from 21.0% the prior year.

Piotroski F-Score Strong

8/9

Resmed passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.25x

For every $1 of reported earnings, Resmed generates $1.25 in operating cash flow ($1.8B OCF vs $1.4B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.1B

YoY+9.8%

5Y CAGR+11.7%

10Y CAGR+11.9%

Resmed generated $5.1B in revenue in fiscal year 2025. This represents an increase of 9.8% from the prior year.

EBITDA

$1.9B

YoY+25.9%

5Y CAGR+14.3%

10Y CAGR+14.6%

Resmed's EBITDA was $1.9B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.9% from the prior year.

Net Income

$1.4B

YoY+37.2%

5Y CAGR+17.6%

10Y CAGR+14.8%

Resmed reported $1.4B in net income in fiscal year 2025. This represents an increase of 37.2% from the prior year.

EPS (Diluted)

$9.51

YoY+37.4%

Resmed earned $9.51 per diluted share (EPS) in fiscal year 2025. This represents an increase of 37.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.7B

YoY+27.6%

5Y CAGR+18.6%

10Y CAGR+17.9%

Resmed generated $1.7B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 27.6% from the prior year.

Cash & Debt

$1.2B

YoY+407.4%

5Y CAGR+21.2%

10Y CAGR+5.4%

Resmed held $1.2B in cash against $658.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

$2.12

YoY+10.4%

Resmed paid $2.12 per share in dividends in fiscal year 2025. This represents an increase of 10.4% from the prior year.

Shares Outstanding

146M

YoY-0.4%

Resmed had 146M shares outstanding in fiscal year 2025. This represents a decrease of 0.4% from the prior year.

Margins & Returns

Gross Margin

59.4%

YoY+2.7pp

5Y CAGR+1.3pp

10Y CAGR-0.9pp

Resmed's gross margin was 59.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.

Operating Margin

32.8%

YoY+4.6pp

5Y CAGR+5.4pp

10Y CAGR+8.4pp

Resmed's operating margin was 32.8% in fiscal year 2025, reflecting core business profitability. This is up 4.6 percentage points from the prior year.

Net Margin

27.2%

YoY+5.4pp

5Y CAGR+6.2pp

10Y CAGR+6.2pp

Resmed's net profit margin was 27.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.4 percentage points from the prior year.

Return on Equity

23.5%

YoY+2.5pp

5Y CAGR-1.4pp

10Y CAGR+1.2pp

Resmed's ROE was 23.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$331.3M

YoY+7.7%

5Y CAGR+10.4%

10Y CAGR+11.2%

Resmed invested $331.3M in research and development in fiscal year 2025. This represents an increase of 7.7% from the prior year.

Share Buybacks

$300.0M

YoY+100.0%

10Y CAGR+6.5%

Resmed spent $300.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 100.0% from the prior year.

Capital Expenditures

$89.9M

YoY-9.6%

5Y CAGR-1.2%

10Y CAGR+3.7%

Resmed invested $89.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 9.6% from the prior year.

RSMDF Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.1B+9.8%	$4.7B+10.9%	$4.2B+18.0%	$3.6B+11.9%	$3.2B+8.1%	$3.0B
Cost of Revenue	$2.1B+3.0%	$2.0B+8.7%	$1.9B+20.2%	$1.6B+14.4%	$1.4B+9.6%	$1.2B
Gross Profit	$3.1B+15.1%	$2.7B+12.7%	$2.4B+16.4%	$2.0B+10.1%	$1.8B+7.1%	$1.7B
R&D Expenses	$331.3M+7.7%	$307.5M+6.9%	$287.6M+13.4%	$253.6M+12.6%	$225.3M+11.6%	$201.9M
SG&A Expenses	$991.0M+8.1%	$917.1M+4.9%	$874.0M+18.5%	$737.5M+10.0%	$670.4M-0.9%	$676.7M
Operating Income	$1.7B+27.7%	$1.3B+16.6%	$1.1B+13.2%	$1.0B+10.7%	$903.7M+11.6%	$809.7M
Interest Expense	N/A	N/A	-$47.4M-112.3%	-$22.3M-193.0%	$24.0M-40.6%	$40.4M
Income Tax	$276.8M+13.5%	$243.8M+19.5%	$204.1M+12.7%	$181.0M-55.8%	$409.2M+267.2%	$111.4M
Net Income	$1.4B+37.2%	$1.0B+13.7%	$897.6M+15.2%	$779.4M+64.3%	$474.5M-23.7%	$621.7M
EPS (Diluted)	$9.51+37.4%	$6.92+13.6%	$6.09+14.9%	$5.30	$3.24	$4.27

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.4B+6.5%	$1.3B-0.9%	$1.3B+4.4%	$1.3B+0.8%	$1.3B+4.7%	$1.2B+0.1%	$1.2B+2.2%	$1.2B
Cost of Revenue	$544.1M+5.7%	$514.8M-2.5%	$527.9M+0.5%	$525.3M-1.0%	$530.8M+4.6%	$507.3M-0.1%	$507.7M+0.7%	$504.2M
Gross Profit	$878.7M+7.1%	$820.8M+0.1%	$820.1M+7.0%	$766.4M+2.0%	$751.3M+4.7%	$717.2M+0.2%	$715.5M+3.3%	$692.8M
R&D Expenses	$91.0M+4.2%	$87.3M+1.0%	$86.4M+3.0%	$83.9M+3.2%	$81.4M+2.3%	$79.5M-1.7%	$80.9M+4.9%	$77.1M
SG&A Expenses	$278.4M+7.4%	$259.2M-2.2%	$265.1M+8.1%	$245.3M+1.5%	$241.6M+1.1%	$239.0M-1.3%	$242.2M+5.3%	$229.9M
Operating Income	$491.7M+10.1%	$446.5M-1.8%	$454.5M+6.6%	$426.3M+2.2%	$417.2M+7.7%	$387.3M+1.6%	$381.2M+1.8%	$374.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$11.0M
Income Tax	$103.6M+5.4%	$98.3M+25.4%	$78.3M+48.8%	$52.7M-28.6%	$73.7M+2.2%	$72.1M+10.1%	$65.5M-12.6%	$74.9M
Net Income	$392.6M+12.6%	$348.5M-8.2%	$379.7M+4.0%	$365.0M+5.9%	$344.6M+10.7%	$311.4M+6.5%	$292.2M-2.7%	$300.5M
EPS (Diluted)	$2.68+13.1%	$2.37	N/A	$2.48+6.0%	$2.34+10.9%	$2.11	N/A	$2.04

RSMDF Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2B+18.9%	$6.9B+1.8%	$6.8B+32.5%	$5.1B+7.8%	$4.7B+3.1%	$4.6B
Current Assets	$3.5B+48.7%	$2.4B-0.4%	$2.4B+22.6%	$1.9B+22.7%	$1.6B+3.4%	$1.5B
Cash & Equivalents	$1.2B+407.4%	$238.4M+4.6%	$227.9M-16.7%	$273.7M-7.3%	$295.3M-36.2%	$463.2M
Inventory	$927.7M+12.8%	$822.3M-17.6%	$998.0M+34.2%	$743.9M+62.8%	$457.0M+9.6%	$416.9M
Accounts Receivable	$939.5M+12.2%	$837.3M+18.8%	$704.9M+22.4%	$576.0M-6.2%	$614.3M+29.4%	$474.6M
Goodwill	$3.0B+7.2%	$2.8B+2.6%	$2.8B+43.1%	$1.9B+0.4%	$1.9B+2.0%	$1.9B
Total Liabilities	$2.2B+9.9%	$2.0B-23.4%	$2.6B+51.1%	$1.7B-5.8%	$1.8B-11.9%	$2.1B
Current Liabilities	$1.0B+11.9%	$910.7M+20.1%	$758.5M+10.0%	$689.3M-24.4%	$911.8M+51.3%	$602.8M
Long-Term Debt	$658.4M-5.6%	$697.3M-51.3%	$1.4B+87.0%	$765.3M+19.0%	$643.4M-44.7%	$1.2B
Total Equity	$6.0B+22.7%	$4.9B+17.8%	$4.1B+22.9%	$3.4B+16.5%	$2.9B+15.6%	$2.5B
Retained Earnings	$6.1B+21.8%	$5.0B+17.4%	$4.3B+17.7%	$3.6B+17.3%	$3.1B+8.7%	$2.8B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$8.5B+2.3%	$8.3B+1.6%	$8.2B+8.0%	$7.6B+6.0%	$7.1B-1.1%	$7.2B+5.1%	$6.9B+0.8%	$6.8B
Current Assets	$3.8B+5.3%	$3.6B+3.4%	$3.5B+9.3%	$3.2B+13.1%	$2.8B+7.4%	$2.6B+12.0%	$2.4B+0.3%	$2.4B
Cash & Equivalents	$1.4B+2.4%	$1.4B+14.4%	$1.2B+29.7%	$932.7M+78.7%	$521.9M+22.4%	$426.4M+78.9%	$238.4M+0.2%	$237.9M
Inventory	$922.0M-2.5%	$945.8M+2.0%	$927.7M+7.5%	$862.6M-2.2%	$882.1M-3.9%	$918.0M+11.6%	$822.3M-0.9%	$829.5M
Accounts Receivable	$985.6M+8.6%	$907.3M-3.4%	$939.5M+3.5%	$907.8M+5.6%	$859.9M+6.0%	$811.2M-3.1%	$837.3M+7.4%	$779.3M
Goodwill	$3.0B0.0%	$3.0B-0.1%	$3.0B+6.9%	$2.8B+1.6%	$2.8B-2.8%	$2.9B+1.5%	$2.8B+0.2%	$2.8B
Total Liabilities	$2.2B-0.2%	$2.2B-0.9%	$2.2B+9.2%	$2.0B+7.0%	$1.9B-6.9%	$2.0B+0.9%	$2.0B-8.1%	$2.2B
Current Liabilities	$1.2B-0.6%	$1.3B+23.2%	$1.0B+8.4%	$940.5M+10.4%	$852.0M-5.8%	$904.1M-0.7%	$910.7M+17.8%	$773.0M
Long-Term Debt	$403.9M-1.2%	$408.7M-37.9%	$658.4M-0.7%	$663.1M0.0%	$662.9M-0.7%	$667.6M-4.3%	$697.3M-30.1%	$997.0M
Total Equity	$6.3B+3.3%	$6.1B+2.6%	$6.0B+7.6%	$5.5B+5.6%	$5.3B+1.1%	$5.2B+6.8%	$4.9B+5.1%	$4.6B
Retained Earnings	$6.6B+4.8%	$6.3B+4.3%	$6.1B+5.2%	$5.8B+5.2%	$5.5B+5.1%	$5.2B+4.7%	$5.0B+4.6%	$4.8B

RSMDF Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.8B+25.0%	$1.4B+102.1%	$693.3M+97.4%	$351.1M-52.3%	$736.7M-8.2%	$802.3M
Capital Expenditures	$89.9M-9.6%	$99.5M-16.9%	$119.7M-11.2%	$134.8M+31.3%	$102.7M+7.7%	$95.3M
Free Cash Flow	$1.7B+27.6%	$1.3B+126.9%	$573.6M+165.2%	$216.3M-65.9%	$634.0M-10.3%	$706.9M
Investing Cash Flow	-$200.0M+25.8%	-$269.8M+76.7%	-$1.2B-404.5%	-$229.9M-45.1%	-$158.5M+11.9%	-$179.9M
Financing Cash Flow	-$606.3M+45.8%	-$1.1B-364.7%	$422.9M+429.4%	-$128.4M+83.2%	-$764.6M-141.0%	-$317.3M
Dividends Paid	$310.9M+10.1%	$282.3M+9.3%	$258.3M+5.3%	$245.3M+8.2%	$226.7M+0.7%	$225.1M
Share Buybacks	$300.0M+100.0%	$150.0M	$0	$0	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$339.7M-25.7%	$457.3M-15.1%	$538.8M-6.9%	$578.7M+87.5%	$308.6M-5.2%	$325.5M-26.0%	$440.1M+9.5%	$402.0M
Capital Expenditures	$28.5M-33.6%	$43.0M+40.5%	$30.6M+47.1%	$20.8M+0.7%	$20.6M+15.7%	$17.8M-28.3%	$24.9M+17.4%	$21.2M
Free Cash Flow	$311.2M-24.9%	$414.4M-18.5%	$508.2M-8.9%	$557.9M+93.7%	$288.0M-6.4%	$307.7M-25.9%	$415.2M+9.0%	$380.8M
Investing Cash Flow	-$50.9M+3.1%	-$52.6M+60.7%	-$133.7M-320.7%	-$31.8M+13.4%	-$36.7M-1809.8%	$2.1M+104.6%	-$46.5M-40.3%	-$33.2M
Financing Cash Flow	-$258.3M-12.2%	-$230.3M-40.5%	-$163.9M-13.8%	-$144.1M+2.3%	-$147.5M+2.1%	-$150.8M+61.7%	-$393.3M-17.1%	-$335.9M
Dividends Paid	$87.6M-0.2%	$87.8M+13.1%	$77.6M-0.1%	$77.7M0.0%	$77.7M-0.3%	$77.9M+10.4%	$70.6M+0.1%	$70.5M
Share Buybacks	$175.0M+16.7%	$150.0M+50.0%	$100.0M+33.3%	$75.0M+0.1%	$75.0M+50.0%	$50.0M0.0%	$50.0M0.0%	$50.0M

RSMDF Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	59.4%+2.7pp	56.7%+0.9pp	55.8%-0.8pp	56.6%-1.0pp	57.5%-0.6pp	58.1%
Operating Margin	32.8%+4.6pp	28.2%+1.4pp	26.8%-1.2pp	28.0%-0.3pp	28.3%+0.9pp	27.4%
Net Margin	27.2%+5.4pp	21.8%+0.5pp	21.3%-0.5pp	21.8%+6.9pp	14.8%-6.2pp	21.0%
Return on Equity	23.5%+2.5pp	21.0%-0.7pp	21.7%-1.5pp	23.2%+6.8pp	16.4%-8.5pp	24.9%
Return on Assets	17.1%+2.3pp	14.9%+1.6pp	13.3%-2.0pp	15.3%+5.3pp	10.0%-3.5pp	13.6%
Current Ratio	3.44+0.9	2.59-0.5	3.12+0.3	2.80+1.1	1.73-0.8	2.53
Debt-to-Equity	0.11-0.0	0.14-0.2	0.35+0.1	0.230.0	0.22-0.2	0.47
FCF Margin	32.3%+4.5pp	27.8%+14.2pp	13.6%+7.5pp	6.0%-13.8pp	19.8%-4.1pp	23.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	61.8%+0.3pp	61.5%+0.6pp	60.8%+1.5pp	59.3%+0.7pp	58.6%+0.0pp	58.6%+0.1pp	58.5%+0.6pp	57.9%
Operating Margin	34.6%+1.1pp	33.4%-0.3pp	33.7%+0.7pp	33.0%+0.5pp	32.5%+0.9pp	31.6%+0.5pp	31.2%-0.1pp	31.3%
Net Margin	27.6%+1.5pp	26.1%-2.1pp	28.2%-0.1pp	28.3%+1.4pp	26.9%+1.4pp	25.4%+1.5pp	23.9%-1.2pp	25.1%
Return on Equity	6.2%+0.5pp	5.7%-0.7pp	6.4%-0.2pp	6.6%+0.0pp	6.6%+0.6pp	6.0%-0.0pp	6.0%-0.5pp	6.5%
Return on Assets	4.6%+0.4pp	4.2%-0.4pp	4.7%-0.2pp	4.8%-0.0pp	4.8%+0.5pp	4.3%+0.1pp	4.3%-0.2pp	4.4%
Current Ratio	3.06+0.2	2.89-0.6	3.44+0.0	3.41+0.1	3.33+0.4	2.92+0.3	2.59-0.5	3.04
Debt-to-Equity	0.060.0	0.07-0.0	0.110.0	0.120.0	0.130.0	0.13-0.0	0.14-0.1	0.22
FCF Margin	21.9%-9.1pp	31.0%-6.7pp	37.7%-5.5pp	43.2%+20.7pp	22.5%-2.7pp	25.1%-8.8pp	34.0%+2.1pp	31.8%

Frequently Asked Questions

What is Resmed's annual revenue?

Resmed (RSMDF) reported $5.1B in total revenue for fiscal year 2025. This represents a 9.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Resmed's revenue growing?

Resmed (RSMDF) revenue grew by 9.8% year-over-year, from $4.7B to $5.1B in fiscal year 2025.

Is Resmed profitable?

Yes, Resmed (RSMDF) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 27.2%.

What is Resmed's EBITDA?

Resmed (RSMDF) had EBITDA of $1.9B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Resmed have?

As of fiscal year 2025, Resmed (RSMDF) had $1.2B in cash and equivalents against $658.4M in long-term debt.

What is Resmed's gross margin?

Resmed (RSMDF) had a gross margin of 59.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Resmed's operating margin?

Resmed (RSMDF) had an operating margin of 32.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Resmed's net profit margin?

Resmed (RSMDF) had a net profit margin of 27.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Resmed pay dividends?

Yes, Resmed (RSMDF) paid $2.12 per share in dividends during fiscal year 2025.

What is Resmed's return on equity (ROE)?

Resmed (RSMDF) has a return on equity of 23.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Resmed's free cash flow?

Resmed (RSMDF) generated $1.7B in free cash flow during fiscal year 2025. This represents a 27.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Resmed's operating cash flow?

Resmed (RSMDF) generated $1.8B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Resmed's total assets?

Resmed (RSMDF) had $8.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Resmed's capital expenditures?

Resmed (RSMDF) invested $89.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Resmed spend on research and development?

Resmed (RSMDF) invested $331.3M in research and development during fiscal year 2025.

Does Resmed buy back shares?

Yes, Resmed (RSMDF) spent $300.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Resmed have outstanding?

Resmed (RSMDF) had 146M shares outstanding as of fiscal year 2025.

What is Resmed's current ratio?

Resmed (RSMDF) had a current ratio of 3.44 as of fiscal year 2025, which is generally considered healthy.

What is Resmed's debt-to-equity ratio?

Resmed (RSMDF) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Resmed's return on assets (ROA)?

Resmed (RSMDF) had a return on assets of 17.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Resmed's Piotroski F-Score?

Resmed (RSMDF) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Resmed's earnings high quality?

Resmed (RSMDF) has an earnings quality ratio of 1.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Resmed?

Resmed (RSMDF) scores 79 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.